State Street Corp. Discloses Initial Stake in Recursion Pharma
Ticker: RXRX · Form: SC 13G · Filed: Jan 24, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | SC 13G |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, SC-13G, biotech, new-position
TL;DR
**State Street just bought into Recursion Pharma, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, has disclosed an initial ownership stake in Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) as of December 31, 2023. This SC 13G filing indicates that State Street now holds a significant, though passive, position in the biotech company. This matters to investors because large institutional holdings can signal confidence in a company's long-term prospects and potentially provide a floor for the stock price due to consistent demand from such funds.
Why It Matters
This filing shows a major institutional investor, State Street Corporation, has taken a position in Recursion Pharmaceuticals, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor has taken a position, which generally reduces risk by providing stability.
Analyst Insight
A smart investor would view this as a positive signal, indicating institutional validation for Recursion Pharmaceuticals, and might consider further research into the company's fundamentals and growth prospects.
Key Players & Entities
- STATE STREET CORPORATION (company) — the reporting person acquiring shares
- RECURSION PHARMACEUTICALS, INC. (company) — the subject company whose shares were acquired
- December 31, 2023 (date) — the date of the event requiring the filing
Forward-Looking Statements
- State Street Corporation will maintain or increase its stake in Recursion Pharmaceuticals over the next year. (STATE STREET CORPORATION) — medium confidence, target: 2025-01-24
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically an 'INITIAL FILING' under Rule 13D-1(B) of the Securities Exchange Act of 1934.
Who is the reporting person in this SC 13G filing?
The reporting person is STATE STREET CORPORATION, with an IRS Identification No. of 042456637.
What is the subject company whose securities are being reported?
The subject company is RECURSION PHARMACEUTICALS, INC., identified by CIK 0001601830 and CUSIP number 75629V104.
What is the title of the class of securities being reported?
The title of the class of securities is 'COMMON STOCK' of Recursion Pharmaceuticals Inc.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 24, 2024 regarding RECURSION PHARMACEUTICALS, INC. (RXRX).